GLP-1 and energy balance: An integrated model of short-term and long-term control

Nature Reviews Endocrinology

Volumn 7, Issue 9, 2011, Pages 507-516

  Barrera, Jason G ^a   Sandoval, Darleen A ^a   D'Alessio, David A ^a   Seeley, Randy J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; LIPOPOLYSACCHARIDE;

BODY WEIGHT; BRAIN STEM; ENERGY BALANCE; FOOD INTAKE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTHALAMUS; INSULIN RELEASE; NERVE CELL; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; RHOMBENCEPHALON; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VAGUS NERVE; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EATING; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RECEPTORS, GLUCAGON;

EID: 80052049014     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.77     Document Type: Review

References (120)

1. Moran, T. H. & Kinzig, K. P. Gastrointestinal satiety signals II. Cholecystokinin. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G183-G188 (2004).
2. Benoit, S. C., Clegg, D. J., Seeley, R. J. & Woods, S. C. Insulin and leptin as adiposity signals. Recent Prog. Horm. Res. 59, 267-285 (2004). (Pubitemid 41327155)
3. Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409-1439 (2007). (Pubitemid 350041474)
4. Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2007). (Pubitemid 46711096)
5. Parker, H. E., Reimann, F. & Gribble, F. M. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev. Mol. Med. 12, e1 (2010).
6. Peters, A. Incretin-based therapies: review of current clinical trial data. Am. J. Med. 123, S28-S37 (2010).
7. Bose, M., Oliván, B., Teixeira, J., Pi-Sunyer, F. X. & Laferrère, B. Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Obes. Surg. 19, 217-229 (2009).
8. Merchenthaler, I., Lane, M. & Shughrue, P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403, 261-280 (1999). (Pubitemid 28566834)
9. Göke, R., Larsen, P. J., Mikkelsen, J. D. & Sheikh, S. P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 7, 2294-2300 (1995).
10. Tang-Christensen, M. et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 271, R848-R856 (1996).
11. Turton, M. D. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72 (1996). (Pubitemid 26008136)
12. Navarro, M. et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J. Neurochem. 67, 1982-1991 (1996). (Pubitemid 26349672)
13. Rinaman, L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am. J. Physiol. 277, R582-R590 (1999). (Pubitemid 29415130)
14. Vrang, N., Phifer, C. B., Corkern, M. M. & Berthoud, H. R. Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R470-R478 (2003). (Pubitemid 36898916)
15. Rinaman, L. & Comer, J. Antagonism of central glucagon-like peptide-1 receptors enhances lipopolysaccharide-induced fever. Auton. Neurosci. 85, 98-101 (2000).
16. Seeley, R. J. et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J. Neurosci. 20, 1616-1621 (2000). (Pubitemid 30220440)
17. Grill, H. J., Carmody, J. S., Amanda Sadacca, L., Williams, D. L. & Kaplan, J. M. Attenuation of lipopolysaccharide anorexia by antagonism of caudal brain stem but not forebrain GLP-1-R. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R1190-R1193 (2004). (Pubitemid 39391064)
18. McMahon, L. R. & Wellman, P. J. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am. J. Physiol. 274, R23-R29 (1998).
19. McMahon, L. R. & Wellman, P. J. Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. Pharmacol. Biochem. Behav. 58, 673-677 (1997). (Pubitemid 27438122)
20. Schick, R. R., Zimmermann, J. P., vorm Walde, T. & Schusdziarra, V. Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R1427-R1435 (2003). (Pubitemid 36617481)
21. Sandoval, D. A., Bagnol, D., Woods, S. C., DAlessio, D. A. & Seeley, R. J. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57, 2046-2054 (2008).
22. Hayes, M. R., Skibicka, K. P. & Grill, H. J. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149, 4059-4068 (2008).
23. Larsen, P. J., Tang-Christensen, M. & Jessop, D. S. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138, 4445-4455 (1997). (Pubitemid 27408493)
24. Kinzig, K. P. et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J. Neurosci. 23, 6163-6170 (2003). (Pubitemid 36875615)
25. Kinzig, K. P., DAlessio, D. A. & Seeley, R. J. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J. Neurosci. 22, 10470-10476 (2002). (Pubitemid 35416883)
26. Zhang, R., Packard, B. A., Tauchi, M., DAlessio, D. A. & Herman, J. P. Glucocorticoid regulation of preproglucagon transcription and RNA stability during stress. Proc. Natl Acad. Sci. USA 106, 5913-5918 (2009).
27. Yamamoto, H. et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110, 43-52 (2002). (Pubitemid 34743464)
28. Nakade, Y., Tsukamoto, K., Pappas, T. N. & Takahashi, T. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res. 1111, 117-121 (2006). (Pubitemid 44331186)
29. Nogueiras, R. et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J. Neurosci. 29, 5916-5925 (2009).
30. Pérez-Tilve, D. et al. Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. Am. J. Physiol. Endocrinol. Metab. 298, E1088-E1096 (2010).
31. Nakade, Y., Tsukamoto, K., Iwa, M., Pappas, T. N. & Takahashi, T. Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats. Auton. Neurosci. 131, 50-56 (2007). (Pubitemid 44960180)
32. Wan, S., Browning, K. N. & Travagli, R. A. Glucagon-like peptide-1 modulates synaptic transmission to identified pancreas-projecting vagal motoneurons. Peptides 28, 2184-2191 (2007). (Pubitemid 47610793)
33. Wan, S., Coleman, F. H. & Travagli, R. A. Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1474-G1482 (2007). (Pubitemid 47080600)
34. Knauf, C. et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J. Clin. Invest. 115, 3554-3563 (2005). (Pubitemid 43121843)
35. Sandoval, D. A., Bagnol, D., Woods, S. C., DAlessio, D. A. & Seeley, R. J. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57, 2046-2054 (2008).
36. Knauf, C. et al. Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes 57, 2603-2612 (2008).
37. Cabou, C. et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57, 2577-2587 (2008).
38. Campos, R. V., Lee, Y. C. & Drucker, D. J. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134, 2156-2164 (1994). (Pubitemid 24142957)
39. Vrang, N., Hansen, M., Larsen, P. J. & Tang-Christensen, M. Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Res. 1149, 118-126 (2007). (Pubitemid 46671416)
40. Gaykema, R. P. et al. Immune challenge and satiety-related activation of both distinct and overlapping neuronal populations in the brainstem indicate parallel pathways for viscerosensory signaling. Brain Res. 1294, 61-79 (2009).
41. Meeran, K. et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140, 244-250 (1999). (Pubitemid 29011165)
42. Scrocchi, L. A. et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2, 1254-1258 (1996). (Pubitemid 26375413)
43. Scrocchi, L. A. & Drucker, D. J. Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice. Endocrinology 139, 3127-3132 (1998). (Pubitemid 28512341)
44. Hansotia, T. et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J. Clin. Invest. 117, 143-152 (2007). (Pubitemid 46048461)
45. Knauf, C. et al. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149, 4768-4777 (2008).
46. Lachey, J. L. et al. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology 146, 458-462 (2005). (Pubitemid 40051771)
47. Barrera, J. G. et al. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like Peptide-1 loss of function. J. Neurosci. 31, 3904-3913 (2011).
48. Shughrue, P. J., Lane, M. V. & Merchenthaler, I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137, 5159-5162 (1996). (Pubitemid 26403362)
49. Shimizu, I., Hirota, M., Ohboshi, C. & Shima, K. Identification and localization of glucagon-like peptide-1 and its receptor in the brain. Endocrinology 121, 1076-1082 (1987). (Pubitemid 17139162)
50. Mentlein, R., Gallwitz, B. & Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, petide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829-835 (1993). (Pubitemid 23188160)
51. Rodriquez de Fonseca, F. et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49, 709-717 (2000).
52. Szayna, M. et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141, 1936-1941 (2000). (Pubitemid 32274340)
53. Thum, A. et al. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp. Clin. Endocrinol. Diabetes 110, 113-118 (2002). (Pubitemid 34461416)
54. Kastin, A. J. & Akerstrom, V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 27, 313-318 (2003). (Pubitemid 36384867)
55. Baggio, L. L., Huang, Q., Brown, T. J. & Drucker, D. J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53, 2492-2500 (2004). (Pubitemid 39145610)
56. Baggio, L. L., Huang, Q., Cao, X. & Drucker, D. J. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 134, 1137-1147 (2008). (Pubitemid 351451971)
57. Baraboi, E. D., Smith, P., Ferguson, A. V. & Richard, D. Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1098-R1110 (2010).
58. Williams, D. L., Baskin, D. G. & Schwartz, M. W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150, 1680-1687 (2009).
59. Scott, K. A. & Moran, T. H. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R983-R987 (2007). (Pubitemid 47358916)
60. Flint, A., Raben, A., Astrup, A. & Holst, J. J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515-520 (1998). (Pubitemid 28084232)
61. Serre, V. et al. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′, 5′-monophosphate levels and β-cell glucose competence. Endocrinology 139, 4448-4454 (1998). (Pubitemid 28487758)
62. Vahl, T. P., Drazen, D. L., Seeley, R. J., DAlessio, D. A. & Woods, S. C. Meal-anticipatory glucagon-like peptide-1 secretion in rats. Endocrinology 151, 569-575 (2009).
63. Nakagawa, A. et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton. Neurosci. 110, 36-43 (2004). (Pubitemid 38180536)
64. Vahl, T. P. et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148, 4965-4973 (2007). (Pubitemid 47481523)
65. Bucinskaite, V. et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol. Motil. 21, 978-e78 (2009).
66. Abbott, C. R. et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 1044, 127-131 (2005). (Pubitemid 40616060)
67. Talsania, T., Anini, Y., Siu, S., Drucker, D. J. & Brubaker, P. L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146, 3748-3756 (2005). (Pubitemid 41175742)
68. Rüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N. & Langhans, W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150, 1174-1181 (2009).
69. Kim, D. H., DAlessio, D. A., Woods, S. C. & Seeley, R. J. The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul. Pept. 155, 110-114 (2009).
70. Rüttimann, E. B., Arnold, M., Geary, N. & Langhans, W. GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats. Physiol. Behav. 100, 291-296 (2009).
71. Washington, M. C., Raboin, S. J., Thompson, W., Larsen, C. J. & Sayegh, A. I. Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor. Brain Res. 1344, 124-133 (2010).
72. Hayes, M. R., Bradley, L. & Grill, H. J. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 150, 2654-2659 (2009).
73. Yamamoto, H. et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J. Neurosci. 23, 2939-2946 (2003). (Pubitemid 36418630)
74. Hisadome, K., Reimann, F., Gribble, F. M. & Trapp, S. Leptin directly depolarizes preproglucagon neurons in the nucleus tractus solitarius: electrical properties of glucagon-like peptide 1 neurons. Diabetes 59, 1890-1898 (2010).
75. Barrachina, M. D., Martnez, V., Wang, L., Wei, J. Y. & Taché, Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc. Natl Acad. Sci. USA 94, 10455-10460 (1997). (Pubitemid 27407063)
76. Emond, M., Schwartz, G. J., Ladenheim, E. E. & Moran, T. H. Central leptin modulates behavioral and neural responsivity to CCK. Am. J. Physiol. 276 (Pt 2), R1545-R1549 (1999). (Pubitemid 29249682)
77. Morton, G. J. et al. Leptin action in the forebrain regulates the hindbrain response to satiety signals. J. Clin. Invest. 115, 703-710 (2005). (Pubitemid 40322245)
78. Williams, D. L., Baskin, D. G. & Schwartz, M. W. Hindbrain leptin receptor stimulation enhances the anorexic response to cholecystokinin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R1238-R1246 (2009).
79. McMinn, J. E., Sindelar, D. K., Havel, P. J. & Schwartz, M. W. Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin. Endocrinology 141, 4442-4448 (2000). (Pubitemid 32055119)
80. Williams, D. L., Baskin, D. G. & Schwartz, M. W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 55, 3387-3393 (2006). (Pubitemid 44923597)
81. Goldstone, A. P. et al. Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents. FEBS Lett. 415, 134-138 (1997). (Pubitemid 27430055)
82. Goldstone, A. P. et al. Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. Biochem. Biophys. Res. Commun. 269, 331-335 (2000). (Pubitemid 30440299)
83. Elias, C. F. et al. Chemical characterization of leptin-activated neurons in the rat brain. J. Comp. Neurol. 423, 261-281 (2000). (Pubitemid 30421790)
84. Nowak, A. & Bojanowska, E. Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite. J. Physiol. Pharmacol. 59, 501-510 (2008).
85. Scrocchi, L. A., Brown, T. J. & Drucker, D. J. Leptin sensitivity in nonobese glucagon-like peptide I receptor -/- mice. Diabetes 46, 2029-2034 (1997). (Pubitemid 27512091)
86. Huo, L., Gamber, K. M., Grill, H. J. & Bjørbaek, C. Divergent leptin signaling in proglucagon neurons of the nucleus of the solitary tract in mice and rats. Endocrinology 149, 492-497 (2008). (Pubitemid 351159324)
87. Vrang, N. et al. Upregulation of the brainstem preproglucagon system in the obese Zucker rat. Brain Res. 1187, 116-124 (2008). (Pubitemid 350199543)
88. Primeaux, S. D., Barnes, M. J., Braymer, H. D. & Bray, G. A. Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats. Int. J. Obes. (Lond.) 34, 1427-1433 (2010).
89. Al-Barazanji, K. A., Arch, J. R., Buckingham, R. E. & Tadayyon, M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes. Res. 8, 317-323 (2000).
90. Ranganath, L. R. et al. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38, 916-919 (1996). (Pubitemid 26231779)
91. Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S. & Holst, J. J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50, 609-613 (2001). (Pubitemid 32195226)
92. Vilsbøll, T. et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 88, 2706-2713 (2003). (Pubitemid 36724446)
93. Anini, Y. & Brubaker, P. L. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52, 252-259 (2003). (Pubitemid 36173176)
94. Muscelli, E. et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57, 1340-1348 (2008).
95. Carr, R. D. et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J. Clin. Endocrinol. Metab. 95, 872-878 (2010).
96. Donahey, J. C., van Dijk, G., Woods, S. C. & Seeley, R. J. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res. 779, 75-83 (1998). (Pubitemid 28039941)
97. Mack, C. M. et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int. J. Obes. (Lond.) 30, 1332-1340 (2006).
98. Lamont, B. J. & Drucker, D. J. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 57, 190-198 (2008).
99. Raun, K. et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56, 8-15 (2007).
100. Flint, A., Raben, A., Astrup, A. & Holst, J. J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515-520 (1998). (Pubitemid 28084232)
101. Näslund, E., Gutniak, M., Skogar, S., Rössner, S. & Hellström, P. M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am. J. Clin. Nutr. 68, 525-530 (1998). (Pubitemid 28402372)
102. Näslund, E. et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. Relat. Metab. Disord. 23, 304-311 (1999). (Pubitemid 29118862)
103. Long, S. J. et al. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. Br. J. Nutr. 81, 273-279 (1999). (Pubitemid 29248498)
104. Gutzwiller, J. P. et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44, 81-86 (1999).
105. Gutzwiller, J. P. et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 276 (Pt 2), R1541-R1544 (1999).
106. Flint, A., Raben, A., Ersbøll, A. K., Holst, J. J. & Astrup, A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. Relat. Metab. Disord. 25, 781-792 (2001). (Pubitemid 32601369)
107. Verdich, C. et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 86, 4382-4389 (2001). (Pubitemid 32848563)
108. Buse, J. B. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628-2635 (2004). (Pubitemid 39441462)
109. Kendall, D. M. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083-1091 (2005). (Pubitemid 40616617)
110. DeFronzo, R. A. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092-1100 (2005).
111. Vilsboll, T. et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30, 1608-1610 (2007). (Pubitemid 46871185)
112. Astrup, A. et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606-1616 (2009).
113. Raz, I. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49, 2564-2571 (2006).
114. Pratley, R. E., Jauffret-Kamel, S., Galbreath, E. & Holmes, D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm. Metab. Res. 38, 423-428 (2006). (Pubitemid 44047965)
115. Rosenstock, J., Sankoh, S. & List, J. F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes. Metab. 10, 376-386 (2008). (Pubitemid 351524285)
116. DeFronzo, R. A., Fleck, P. R., Wilson, C. A. & Mekki, Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31, 2315-2317 (2008).
117. Taskinen, M. R. et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab. 13, 65-74 (2011).
118. Aaboe, K. et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 12, 323-333 (2010).
119. Buse, J. B. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39-47 (2009).
120. Barrera, J. G., DAlessio, D. A., Drucker, D. J., Woods, S. C. & Seeley, R. J. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 58, 2820-2827 (2009).